Congratulations to our collaborators, Dr. Xiao He, Dr. Hong Zhang and Dr. Mei Tian! This cutting-edge and delegate study of iPSC-derived forebrain neural progenitor cell hNPC01 was published in Nature Communications on June 3rd and supported that hNPC01 progeny cells integrated into rat neural circuits. Moreover, the phase 1 clinical study of hNPC01 injection treating chronic ischemic stroke is about to complete 12-months observation of all subjects by the end of June, with IND clearance from NMPA and FDA in 2023 and 2024. Dr. Jing Fan, the founder of Hopstem, will present the exciting clinical data of hNPC01 at the upcoming Bio Congress in Boston, in Room 153C at 11:45 a.m. on June 17. If you are interested in collaboration on RMAT innovative iPSC cell therapy targeting chronic stroke and other CNS diseases, please talk to Dr. Fan at Bio or feel free to contact us online.
Link of publication: https://www.nature.com/articles/s41467-025-60187-5
Mechanism study of hNPC01 neural progenitor cell grafting therapy in a rat ischemic stroke model was published in Nature Communications
Hopstem Won First Place at 2024 SAPA Investment Forum & online Road Show with Innovative iPSC Cell Therapy for Chronic Stroke
Hopstem Biotechnology at 2024 CASSS CGPT Symposium
Hopstem Biotechnology to Participate in the 2024 BIO International Convention in San Diego
R&D Center: Building 11,Heda Medicine Valley V, Qiantang Area,
Hangzhou, Zhejiang, China
Manufacturing Center: 3rd & 4th Floor, Building 10,Heda Medicine Valley lll,
Qiantang Area, Hangzhou, Zhejiang, China
U.S. Office: 103 Carnegie center, Suite 300, Princeton,
NJ 08540, USA
